IL162509A0 - Use of deoxypeganine for treating clinical depression - Google Patents

Use of deoxypeganine for treating clinical depression

Info

Publication number
IL162509A0
IL162509A0 IL16250902A IL16250902A IL162509A0 IL 162509 A0 IL162509 A0 IL 162509A0 IL 16250902 A IL16250902 A IL 16250902A IL 16250902 A IL16250902 A IL 16250902A IL 162509 A0 IL162509 A0 IL 162509A0
Authority
IL
Israel
Prior art keywords
deoxypeganine
clinical depression
treating clinical
treating
depression
Prior art date
Application number
IL16250902A
Other languages
English (en)
Original Assignee
Hf Arzneimittelforsch Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hf Arzneimittelforsch Gmbh filed Critical Hf Arzneimittelforsch Gmbh
Publication of IL162509A0 publication Critical patent/IL162509A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
IL16250902A 2001-12-21 2002-12-14 Use of deoxypeganine for treating clinical depression IL162509A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10163667A DE10163667B4 (de) 2001-12-21 2001-12-21 Verwendung von Desoxypeganin zur Behandlung der klinischen Depression
PCT/EP2002/014274 WO2003053445A1 (de) 2001-12-21 2002-12-14 Verwendung von desoxypeganin zur behandlung der klinischen depression

Publications (1)

Publication Number Publication Date
IL162509A0 true IL162509A0 (en) 2005-11-20

Family

ID=7710660

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16250902A IL162509A0 (en) 2001-12-21 2002-12-14 Use of deoxypeganine for treating clinical depression
IL162509A IL162509A (en) 2001-12-21 2004-06-14 Use of deoxypeganine for the production of a drug for treating clinical depression

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL162509A IL162509A (en) 2001-12-21 2004-06-14 Use of deoxypeganine for the production of a drug for treating clinical depression

Country Status (30)

Country Link
US (1) US20050009813A1 (xx)
EP (1) EP1461042B1 (xx)
JP (1) JP2005513105A (xx)
KR (1) KR100614504B1 (xx)
CN (1) CN1283253C (xx)
AR (1) AR037967A1 (xx)
AT (1) ATE404203T1 (xx)
AU (1) AU2002363874B2 (xx)
BR (1) BR0215306A (xx)
CA (1) CA2471338C (xx)
CZ (1) CZ301210B6 (xx)
DE (2) DE10163667B4 (xx)
DK (1) DK1461042T3 (xx)
EA (1) EA006896B1 (xx)
ES (1) ES2312657T3 (xx)
HK (1) HK1066742A1 (xx)
HU (1) HUP0402298A3 (xx)
IL (2) IL162509A0 (xx)
MX (1) MXPA04006125A (xx)
MY (1) MY138088A (xx)
NO (1) NO326446B1 (xx)
NZ (1) NZ533249A (xx)
PL (1) PL370315A1 (xx)
PT (1) PT1461042E (xx)
SI (1) SI1461042T1 (xx)
SK (1) SK287152B6 (xx)
TW (1) TWI241189B (xx)
UA (1) UA76254C2 (xx)
WO (1) WO2003053445A1 (xx)
ZA (1) ZA200404053B (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
WO2004056363A2 (en) 2002-12-20 2004-07-08 Niconovum Ab A physically and chemically stable nicotine-containing particulate material
DE10354893B4 (de) * 2003-11-24 2011-03-10 Hf Arzneimittelforschung Gmbh Verwendung von Desoxypeganin zur Behandlung schizophrener Psychosen
DE10354894A1 (de) * 2003-11-24 2005-07-07 Hf Arzneimittelforschung Gmbh Orale Formulierungen des Desoxypeganins und deren Anwendungen
FR2865650B1 (fr) * 2004-01-30 2008-06-13 Biocortech Utilisation du 14,15 dihydro 20,21-dinoreburnamenin14-ol pour traiter et/ou prevenir les depressions majeures et les desordres du cycle veille-sommeil
JP5000932B2 (ja) * 2005-06-21 2012-08-15 日東電工株式会社 ニコチン含有経皮吸収製剤
CA2646942C (en) 2006-03-16 2014-07-29 Niconovum Ab Improved snuff composition
CN101433565B (zh) * 2008-11-26 2013-06-05 上海中医药大学 骆驼蓬属种子总生物碱提取物和它们的制备

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19906979B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit
DE19906977C1 (de) * 1999-02-19 2000-06-15 Lohmann Therapie Syst Lts Desoxypeganin-TTS und seine Verwendung
DE19906975B4 (de) * 1999-02-19 2004-04-15 Lts Lohmann Therapie-Systeme Ag Arzneiform zur Behandlung von Alzheimer'scher Demenz
DE19906978B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit
DE19906974C2 (de) * 1999-02-19 2003-10-09 Lohmann Therapie Syst Lts Verwendung von Desoxypeganin zur Behandlung des Alkoholismus

Also Published As

Publication number Publication date
NO20042476L (no) 2004-06-14
IL162509A (en) 2010-06-16
SI1461042T1 (sl) 2009-02-28
DK1461042T3 (da) 2008-12-01
CA2471338A1 (en) 2003-07-03
WO2003053445A1 (de) 2003-07-03
JP2005513105A (ja) 2005-05-12
NO326446B1 (no) 2008-12-08
MXPA04006125A (es) 2005-05-16
KR100614504B1 (ko) 2006-08-22
ES2312657T3 (es) 2009-03-01
ZA200404053B (en) 2004-10-12
HUP0402298A2 (hu) 2005-02-28
DE10163667B4 (de) 2006-10-26
CN1283253C (zh) 2006-11-08
NZ533249A (en) 2007-05-31
ATE404203T1 (de) 2008-08-15
AU2002363874B2 (en) 2007-12-13
CA2471338C (en) 2009-02-24
EA200400751A1 (ru) 2004-12-30
US20050009813A1 (en) 2005-01-13
WO2003053445A8 (de) 2004-07-01
TWI241189B (en) 2005-10-11
TW200301124A (en) 2003-07-01
EA006896B1 (ru) 2006-04-28
PL370315A1 (en) 2005-05-16
MY138088A (en) 2009-04-30
PT1461042E (pt) 2008-11-03
HUP0402298A3 (en) 2011-03-28
EP1461042B1 (de) 2008-08-13
CN1604781A (zh) 2005-04-06
CZ301210B6 (cs) 2009-12-09
DE50212649D1 (de) 2008-09-25
SK287152B6 (sk) 2010-01-07
DE10163667A1 (de) 2003-07-10
AU2002363874A1 (en) 2003-07-09
HK1066742A1 (en) 2005-04-01
UA76254C2 (en) 2006-07-17
BR0215306A (pt) 2004-12-21
KR20040068327A (ko) 2004-07-30
SK2582004A3 (en) 2004-12-01
CZ2004739A3 (cs) 2004-12-15
AR037967A1 (es) 2004-12-22
EP1461042A1 (de) 2004-09-29

Similar Documents

Publication Publication Date Title
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
GB2393202B (en) Methods of well treatment
IL160884A0 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
EP1416961A4 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF A DISEASE
HK1091840A1 (en) Methods and compositions for therapeutic use of rna interference
EP1390029A4 (en) PHENYLINDOLES FOR THE TREATMENT OF HIV INFECTION
IL158251A0 (en) Treatment of collagen
GB0121155D0 (en) Treatment of substrates
EP1368024A4 (en) TREATMENT OF RESTENOSIS
HUP0400024A2 (hu) Neoplasztikus betegségek kezelésére szolgáló gyógyszerkombinációk
HUP0500734A3 (en) Use of 2-alkoxyphenyl-substituted imidazotriazinones
IL162509A0 (en) Use of deoxypeganine for treating clinical depression
GB0124124D0 (en) Methods of treatment
IL161748A0 (en) New use for the treatment of gastroesophageal reflux
IL188485A0 (en) New use of iloperidone
GB0113910D0 (en) Treatment of liquids
EP1435962A4 (en) TREATMENT OF DIABETES TYPE I
GB0101146D0 (en) Treatment of skin conditions
IL149705A0 (en) Combination treatment for depression and anxiety
IL161630A0 (en) Methods of treating endometreosis
NZ528896A (en) Treatment of ADHD
GB0100092D0 (en) Treatment of degenerative diseases
AU2002367463A8 (en) Novel p53bp2 compounds for therapy and diagnosis and methods for using same
GB0120654D0 (en) Treatment of anemia
HU0104370D0 (en) Honeyed schnaps of oerseg